Combination of β-glucan with a lung cancer vaccine 1650-G and GM-CSF as an adjuvant for a Stage I-IIA Non-Small Cell Lung Cancer (NSCLC) patients of phase I/II clinical trial also showed promising outcomes. The gene discussed is CSF2; the disease is non-small cell lung carcinoma.